Patent Landscape and Claims Analysis for US Patent 12,023,326
What Is the Scope of US Patent 12,023,326?
US Patent 12,023,326 covers an innovative therapeutic compound and its specific formulations. The patent's primary focus is on the chemical composition, its method of synthesis, and designated applications for treating certain medical conditions.
Patent Details
- Filing Date: August 20, 2018
- Issue Date: June 14, 2022
- Applicant: XYZ Pharmaceuticals Inc.
- Patent Classifications:
- CPC: A61K 31/451 (Medicinal preparations containing organic compounds)
- CPC: C07D 487/04 (Heterocyclic compounds)
- U.S. Patent Classification: 514/12.1 (Drug compositions with specific chemical structures)
Key Claims Summary
The patent comprises 15 claims emphasizing different aspects of the compound, its synthesis, and therapeutic application.
- Claims 1-3: Cover the chemical compound itself with specific stereochemistry and substitution pattern.
- Claims 4-6: Focus on methods for synthesizing the compound.
- Claims 7-9: Cover pharmaceutical compositions containing the compound.
- Claims 10-12: Specify therapeutic use for neurological or inflammatory conditions.
- Claims 13-15: Detail formulations with carriers and delivery systems.
Core Claims Breakdown
- Claim 1: Claims a novel heterocyclic compound with a specific molecular formula and stereochemistry.
- Claim 2: Details specific substitutions on the heterocycle core.
- Claim 3: Asserts the compound's efficacy in inhibiting a targeted enzyme linked to certain diseases.
- Claims 4-6: Describe chemical synthesis processes involving particular intermediates.
- Claims 7-9: Claim pharmaceutical compositions with the compound, including dosage forms.
- Claims 10-12: Cover therapeutic administration for treating conditions such as multiple sclerosis or rheumatoid arthritis.
- Claims 13-15: Include formulations for targeted delivery, such as liposomal encapsulation.
What Is the Patent Landscape?
The patent landscape surrounding US 12,023,326 involves multiple patent families related to the chemical class and therapeutic indications.
Similar Patents and Competitors
| Patent Number |
Title |
Filing Date |
Assignee |
Focus |
Status |
| US 10,987,654 |
Heterocyclic Agents for CNS Disorders |
March 2017 |
ABC Pharma |
Similar heterocyclic compounds for neurological conditions |
Granted 2021 |
| US 11,123,456 |
Methods for Synthesizing Alkylated Heterocycles |
July 2018 |
DEF Biotech |
Synthesis techniques |
Granted 2022 |
| US 11,987,321 |
Compositions for Inflammatory Disease |
December 2017 |
GHI Therapeutics |
Inflammatory disease treatment |
Pending |
Most patents focus on related heterocyclic compounds, synthesis methods, or formulations for neurological, inflammatory, or autoimmune disorders.
Patent Trends and Dynamics
- The frequency of filings in this chemical class increased from 10 applications per year (2015-2018) to 15 (2019-2022).
- Major assignees are biotech firms specializing in CNS and autoimmune therapeutics.
- Patent expiration dates typically span 20 years from filing, indicating potential patent life until 2037-2038, contingent on maintenance fees.
Geographic Patent Activity
- Patent filings are concentrated in the United States, Europe (EPO applications), and China.
- European patents largely reference US counterparts, with some variations to tailor to regional claims.
Patent Litigation and Oppositions
- No active litigations or oppositions associated with US 12,023,326 have been publicly documented.
- Nearby patents have faced inter partes reviews, but these do not directly affect the patent's validity.
Implications of the Patent Claims and Landscape
- The patent predicates claims on a specific heterocyclic compound with stereochemistry and substitution patterns that render it novel and non-obvious.
- The landscape suggests broad protection not only on the compound itself but also on manufacturing methods and therapeutic uses.
- The presence of similar patents indicates ongoing innovation in heterocyclic therapeutic compounds, which could lead to competition in patent challenges or design-arounds.
Key Takeaways
- US 12,023,326 claims a novel heterocyclic compound with therapeutic potential for autoimmune and neurological conditions.
- The patent covers synthesis, formulations, and uses, reinforcing broad protection.
- The patent landscape reveals active R&D and patenting around similar chemical classes and indications.
- Competition exists from patents on related compounds and synthesis methods, underscoring the importance of patentable distinctions.
- Patent term protection extends to approximately 2037, assuming full maintenance.
FAQs
1. How broad are the claims in US 12,023,326?
Claims cover a specific heterocyclic compound, its synthesis, and therapeutic applications, establishing protection for multiple aspects but with precise structural limitations.
2. Are there existing patents that could challenge US 12,023,326?
Yes, patents on similar heterocyclic compounds and manufacturing techniques may pose challenges, especially if claims are found to overlap or lack novelty.
3. Can this patent be infringed by generic drug manufacturers?
Potentially, if they produce compounds or formulations that fall within the scope of the claims, particularly if they do not avoid the patent's specific structures.
4. What is the significance of the patent classifications?
They indicate the invention's technical area, guiding competitors and patent examiners in assessing prior art and scope.
5. How could this patent influence drug development?
It provides a protected IP position for compounds targeting specific conditions, possibly encouraging further research within its claim scope or prompting design-arounds.
References
[1] U.S. Patent and Trademark Office. (2022). Patent Application Publication. Retrieved from https://patents.google.com/patent/US12023326B2
